circRNA 001306 enhances hepatocellular carcinoma growth by up‐regulating CDK16 expression via sponging miR‐584‐5p

Liu, Qian; Wang, Cixiao; Jiang, Zhongchao; Li, Shan; Li, Fang; Tan, Huabing; Yue, Su-Yang

doi:10.1111/jcmm.16047

Cited by 20 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 , 33 , 34 , 35 , 36 Increasing studies showed that circRNAs involved in the development of many diseases including cancers, neurological diseases, congenital diseases, intervertebral disc degeneration and endocrine diseases. 37 , 38 , 39 , 40 , 41 , 42 , 43 Recently, studies indicated that circRNAs also play important roles in osteoporosis. 44 …”

Section: Introductionmentioning

confidence: 99%

Emerging roles of circular RNAs in osteoporosis

Chen

Zhang

Chang

2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

Osteoporosis is one bone disease characterized with skeletal impairment, bone strength reduced and fracture risk enhanced. [1][2][3][4] It is accompanied or asymptomatic by mild or serious symptoms, which is one cause of pathological fracture and also the high-risk factor influencing human health. [5][6][7] The incidence of osteoporosis is 70% in people over 80 years and 15% in people over 50 years old. 8,9 The osteoporosis patient's number exceeds 200 million worldwide at present, while the number may increase to 300 million as ageing population by 2023. 10 The modulation processes of bone metabolism are associated with several factors such as mechanical stimulation, epigenetic regulation and hormones. [11][12][13][14][15] The major therapies of osteoporosis are drug therapy and surgery, while the curative effect remains unsatisfactory. [16][17][18] Thus, it is crucial to find new biomarkers for the indention and therapy of osteoporosis.Circular RNAs (circRNAs) are formed by reverse splicing of splice accepter at 5′ end splice donor at the 3′ end in the pre-mRNA. [19][20][21][22] cir-cRNAs are one group of noncoding RNA and temporal, disease specific and spatial are expressed in several tissues and cells and can be acted as therapeutic targets and biomarkers. [23][24][25][26] Although circRNAs are mostly located in cytoplasm, some circRNAs containing introns are originated from nucleus. 27 CircRNAs have several functions including regulating gene transcription, regulating translation, modulating alternative splicing, functioning as miRNA sponges and interacting with RBPs (RNAbinding proteins). [28][29][30][31][32] Growing evidence suggested that circRNAs play crucial roles in cell functions such as cell metabolism, differentiation, proliferation, apoptosis and invasion. 19,[33][34][35][36] Increasing studies showed that circRNAs involved in the development of many diseases including cancers, neurological diseases, congenital diseases, intervertebral disc degeneration and endocrine diseases. [37][38][39][40][41][42][43] Recently, studies indicated that circRNAs also play important roles in osteoporosis. 44

show abstract

Section: Introductionmentioning

confidence: 99%

Emerging roles of circular RNAs in osteoporosis

Chen

Zhang

Chang

2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…It has been widely revealed that circRNAs are of vital importance in biological functions of various cancers through interacting with miRNAs, which can serve as ceRNAs [ 10 – 12 ]. For example, the upregulated circ_001306 could enhance cell proliferation of HCC through interacting with miR-584-5p/CDK16 signaling pathway [ 10 ]. Therefore, we analyzed the potential downstream miRNAs of circ_0067835, which illustrated that miR-1236-3p might be one of them.…”

Section: Discussionmentioning

confidence: 99%

The Elevated Circ_0067835 Could Accelerate Cell Proliferation and Metastasis via miR-1236-3p/Twist2 Axis in Hepatocellular Carcinoma

Chen

2022

BioMed Research International

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a malignant cancer with leading mortality worldwide. Circ_0067835 is a circRNA which plays an important role in various kinds of tumor, while the potential functions of circ_0067835 in HCC remains unclear. In this study, our results of microarray and real-time PCR (RT-PCR) showed that it was obviously elevated in human HCC tumor tissues and HCC cell lines. Inhibition of circ_0067835 restrained cell proliferation and migration in vitro. Furthermore, miR-1236-3p was decreased in tumor samples, and it was indicated to be a target of circ_0067835. Moreover, Twist2 was established to be elevated in HCC tissues, and we identified it as the direct target of miR-1236-3p. Finally, we found that knockdown of miR-1236-3p could reverse the circ_0067835 inhibition effects in HCC cells. In conclusion, our study demonstrated that circ_0067835 contributed to promoting hepatocellular carcinoma cell proliferation and metastasis through downregulating miR-1236-3p expression and then elevating Twist2 expression, which might provide a new vision for HCC patients.

show abstract

“…Covalently bound CDK inhibitors can usually achieve higher activity and selectivity, leading to longer-lasting therapeutic effects and a possible reduction in serious side effects. The first of these inhibitors to be synthesized was THZ1 (43), which contains an N-phenyl-pyrimidin-2-amine backbone, the common core of many potent kinase inhibitors, such as imatinib. 172 The primarily hydrophobic binding pocket of CDK7, which originally accommodates the bound ATP, is occupied by 43.…”

Section: Launched and Clinical Cdk Inhibitorsmentioning

confidence: 99%

From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy

et al. 2022

View full text Add to dashboard Cite

Herein, we discuss more than 50 cyclin-dependent kinase (CDK) inhibitors that have been approved or have undergone clinical trials and their therapeutic application in multiple cancers. This review discusses the design strategies, structure–activity relationships, and efficacy performances of these selective or nonselective CDK inhibitors. The theoretical basis of early broad-spectrum CDK inhibitors is similar to the scope of chemotherapy, but because their toxicity is greater than the benefit, there is no clinical therapeutic window. The notion that selective CDK inhibitors have a safer therapeutic potential than pan-CDK inhibitors has been widely recognized during the research process. Four CDK4/6 inhibitors have been approved for the treatment of breast cancer or for prophylactic administration during chemotherapy to protect bone marrow and immune system function. Furthermore, the emerging strategies in the field of CDK inhibitors are summarized briefly, and CDKs continue to be widely pursued as emerging anticancer drug targets for drug discovery.

show abstract

circRNA 001306 enhances hepatocellular carcinoma growth by up‐regulating CDK16 expression via sponging miR‐584‐5p

Cited by 20 publications

References 25 publications

Emerging roles of circular RNAs in osteoporosis

Emerging roles of circular RNAs in osteoporosis

The Elevated Circ_0067835 Could Accelerate Cell Proliferation and Metastasis via miR-1236-3p/Twist2 Axis in Hepatocellular Carcinoma

From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy

Contact Info

Product

Resources

About